Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price Target & Predictions
ARWR Stock Forecast
Arrowhead Pharmaceuticals stock forecast is as follows: an average price target of $45.38 (represents a 111.17% upside from ARWR’s last price of $21.49) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
ARWR Price Target
The average price target for Arrowhead Pharmaceuticals (ARWR) is $45.38 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $75.00 to $27.00. This represents a potential 111.17% upside from ARWR's last price of $21.49.
ARWR Analyst Ratings
According to 10 Wall Street analysts, Arrowhead Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ARWR stock is 0 'Strong Buy' (0.00%), 7 'Buy' (70.00%), 3 'Hold' (30.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Arrowhead Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | David Lebowitz | Citigroup | $27.00 | $22.91 | 17.85% | 25.64% |
| Jul 05, 2024 | Patrick Trucchio | H.C. Wainwright | $60.00 | $25.57 | 134.65% | 179.20% |
| Jun 05, 2024 | Andrea Tan | Goldman Sachs | $31.00 | $25.29 | 22.58% | 44.25% |
| May 30, 2024 | Luca Issi | RBC Capital | $50.00 | $22.87 | 118.63% | 132.67% |
| Feb 07, 2023 | - | RBC Capital | $77.00 | $32.94 | 133.76% | 258.31% |
| Feb 07, 2023 | - | Piper Sandler | $52.00 | $33.51 | 55.18% | 141.97% |
| Dec 06, 2022 | - | H.C. Wainwright | $90.00 | $31.52 | 185.53% | 318.80% |
| Nov 29, 2022 | - | Jefferies | $75.00 | $29.99 | 150.08% | 249.00% |
| Nov 29, 2022 | - | Morgan Stanley | $37.00 | $28.00 | 32.14% | 72.17% |
| Nov 29, 2022 | - | Leerink Partners | $31.00 | $28.00 | 10.71% | 44.25% |
The latest Arrowhead Pharmaceuticals stock forecast, released on Sep 03, 2024 by David Lebowitz from Citigroup, set a price target of $27.00, which represents a 17.85% increase from the stock price at the time of the forecast ($22.91), and a 25.64% increase from ARWR last price ($21.49).
Arrowhead Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 4 |
| Avg Price Target | $27.00 | $43.50 | $42.00 |
| Last Closing Price | $21.49 | $21.49 | $21.49 |
| Upside/Downside | 25.64% | 102.42% | 95.44% |
In the current month, the average price target of Arrowhead Pharmaceuticals stock is $27.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 25.64% increase as opposed to Arrowhead Pharmaceuticals's last price of $21.49. This month's average price target is down -37.93% compared to last quarter, and down -35.71% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 03, 2024 | Citigroup | Neutral | Neutral | Hold |
| Aug 21, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 05, 2024 | Goldman Sachs | - | Neutral | Initialise |
| May 30, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 20, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 13, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Arrowhead Pharmaceuticals's last stock rating was published by H.C. Wainwright on Sep 04, 2024. The company gave ARWR a "Buy" rating, the same as its previous rate.
Arrowhead Pharmaceuticals Financial Forecast
Arrowhead Pharmaceuticals Revenue Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $3.55M | $16.10M | $15.82M | $146.27M | $62.55M | $31.57M | - | $151.81M | $27.44M | $38.28M | $45.89M | $32.81M | $21.30M | $7.63M | $27.38M | $23.53M | $29.45M | $43.29M | $42.70M | $48.15M | $34.66M | $727.38K | $650.13K |
| Avg Forecast | $29.99M | $24.51M | $18.74M | $15.49M | $55.49M | $52.87M | $41.97M | $33.87M | $44.63M | $45.42M | $45.48M | $162.52M | $50.30M | $45.75M | $122.15M | $47.81M | $42.19M | $43.47M | $39.42M | $106.12M | $57.76M | $30.42M | $22.16M | $31.08M | $40.98M | $54.37M | $42.92M | $143.96M | $730.00K | $650.00K |
| High Forecast | $29.99M | $24.51M | $18.74M | $15.49M | $125.36M | $52.87M | $41.97M | $68.58M | $179.39M | $45.42M | $45.48M | $162.52M | $50.30M | $45.75M | $228.61M | $89.49M | $78.96M | $81.36M | $73.78M | $198.61M | $108.10M | $56.94M | $41.47M | $58.18M | $76.69M | $101.75M | $80.33M | $172.76M | $876.00K | $780.00K |
| Low Forecast | $29.99M | $24.51M | $18.74M | $15.49M | $9.63M | $52.87M | $41.97M | $838.37K | $3.52M | $45.42M | $45.48M | $162.52M | $50.30M | $45.75M | $30.28M | $11.85M | $10.46M | $10.78M | $9.77M | $26.31M | $14.32M | $7.54M | $5.49M | $7.71M | $10.16M | $13.48M | $10.64M | $115.17M | $584.00K | $520.00K |
| # Analysts | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 3 | 4 | 8 | 5 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 15 | 15 |
| Surprise % | - | - | - | - | - | - | - | 0.10% | 0.36% | 0.35% | 3.22% | 0.38% | 0.63% | - | 1.24% | 0.57% | 0.91% | 1.06% | 0.83% | 0.20% | 0.13% | 0.90% | 1.06% | 0.95% | 1.06% | 0.79% | 1.12% | 0.24% | 1.00% | 1.00% |
Arrowhead Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $41.97M, with a low forecast of $41.97M, and a high forecast of $41.97M. ARWR's average Quarter revenue forecast represents a 1081.94% increase compared to the company's last Quarter revenue of $3.55M (Dec 23).
Arrowhead Pharmaceuticals EBITDA Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 3 | 4 | 8 | 5 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 15 | 15 |
| EBITDA | - | - | - | - | - | - | - | $-129.06M | $-99.87M | $-94.95M | $55.40M | $-42.13M | $-83.83M | - | $44.15M | $-60.30M | $-60.87M | $-27.93M | $-24.90M | $-18.88M | $-46.66M | $-12.07M | $-18.46M | $-1.41M | $12.96M | $21.34M | $25.07M | $13.21M | $-14.43M | $-13.73M |
| Avg Forecast | $-18.70M | $-15.28M | $-11.69M | $-9.66M | $-34.60M | $-32.97M | $-26.17M | $-21.12M | $-27.83M | $-28.32M | $-28.36M | $-101.34M | $-284.12M | $-28.53M | $-76.17M | $-40.20M | $-224.60M | $-40.84M | $-27.39M | $-62.32M | $-251.94M | $-11.07M | $-9.57M | $-1.41M | $17.01M | $27.23M | $18.47M | $20.92M | $-14.43M | $-13.73M |
| High Forecast | $-18.70M | $-15.28M | $-11.69M | $-9.66M | $-6.00M | $-32.97M | $-26.17M | $-522.79K | $-2.19M | $-28.32M | $-28.36M | $-101.34M | $-227.30M | $-28.53M | $-18.88M | $-32.16M | $-179.68M | $-32.67M | $-21.91M | $-49.85M | $-201.55M | $-8.85M | $-7.66M | $-1.13M | $20.41M | $32.67M | $22.17M | $25.11M | $-11.54M | $-10.98M |
| Low Forecast | $-18.70M | $-15.28M | $-11.69M | $-9.66M | $-78.17M | $-32.97M | $-26.17M | $-42.76M | $-111.87M | $-28.32M | $-28.36M | $-101.34M | $-340.95M | $-28.53M | $-142.56M | $-48.24M | $-269.52M | $-49.01M | $-32.87M | $-74.78M | $-302.33M | $-13.28M | $-11.49M | $-1.70M | $13.61M | $21.78M | $14.78M | $16.74M | $-17.32M | $-16.48M |
| Surprise % | - | - | - | - | - | - | - | 6.11% | 3.59% | 3.35% | -1.95% | 0.42% | 0.30% | - | -0.58% | 1.50% | 0.27% | 0.68% | 0.91% | 0.30% | 0.19% | 1.09% | 1.93% | 1.00% | 0.76% | 0.78% | 1.36% | 0.63% | 1.00% | 1.00% |
5 analysts predict ARWR's average Quarter EBITDA for Jun 23 to be $-28.32M, with a high of $-28.32M and a low of $-28.32M. This is -151.13% lower than Arrowhead Pharmaceuticals's previous annual EBITDA (Mar 23) of $55.40M.
Arrowhead Pharmaceuticals Net Income Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 3 | 4 | 8 | 5 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 15 | 15 |
| Net Income | - | - | - | - | - | - | - | $-132.86M | $-109.68M | $-102.95M | $48.67M | $-41.81M | $-85.94M | - | $44.37M | $-62.87M | $-63.37M | $-29.92M | $-26.82M | $-20.73M | $-48.43M | $-13.61M | $-19.84M | $-2.67M | $11.70M | $20.34M | $23.90M | $12.04M | $-15.61M | $-14.88M |
| Avg Forecast | $-141.99M | $-152.46M | $-159.66M | $-158.33M | $-120.62M | $-65.69M | $248.71M | $-99.49M | $-75.59M | $-70.71M | $266.00M | $45.94M | $-295.82M | $-70.10M | $284.50M | $-41.91M | $-233.85M | $-43.76M | $-29.50M | $-68.42M | $-261.54M | $-12.48M | $-10.29M | $-2.67M | $15.36M | $25.95M | $17.61M | $19.06M | $-15.61M | $-14.88M |
| High Forecast | $-141.99M | $-152.46M | $-159.66M | $-158.33M | $103.39M | $-65.69M | $298.46M | $-36.99M | $94.48M | $-70.71M | $319.21M | $45.94M | $-236.66M | $-70.10M | $341.40M | $-33.53M | $-187.08M | $-35.01M | $-23.60M | $-54.73M | $-209.23M | $-9.98M | $-8.23M | $-2.14M | $18.44M | $31.13M | $21.13M | $22.87M | $-12.48M | $-11.91M |
| Low Forecast | $-141.99M | $-152.46M | $-159.66M | $-158.33M | $-285.28M | $-65.69M | $198.97M | $-142.85M | $-124.72M | $-70.71M | $212.80M | $45.94M | $-354.98M | $-70.10M | $227.60M | $-50.30M | $-280.62M | $-52.52M | $-35.40M | $-82.10M | $-313.84M | $-14.97M | $-12.34M | $-3.21M | $12.29M | $20.76M | $14.09M | $15.25M | $-18.73M | $-17.86M |
| Surprise % | - | - | - | - | - | - | - | 1.34% | 1.45% | 1.46% | 0.18% | -0.91% | 0.29% | - | 0.16% | 1.50% | 0.27% | 0.68% | 0.91% | 0.30% | 0.19% | 1.09% | 1.93% | 1.00% | 0.76% | 0.78% | 1.36% | 0.63% | 1.00% | 1.00% |
Arrowhead Pharmaceuticals's average Quarter net income forecast for Jun 23 is $-70.71M, with a range of $-70.71M to $-70.71M. ARWR's average Quarter net income forecast represents a -245.26% decrease compared to the company's last Quarter net income of $48.67M (Mar 23).
Arrowhead Pharmaceuticals SG&A Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 3 | 4 | 8 | 5 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 15 | 15 |
| SG&A | - | - | - | - | - | - | - | $23.19M | $24.17M | $23.37M | $22.82M | $20.98M | $33.24M | - | $33.86M | $24.59M | $38.29M | $17.86M | $16.19M | $8.65M | $14.27M | $10.75M | $16.33M | $10.79M | $10.27M | $4.81M | $5.33M | $6.13M | $4.59M | $3.68M |
| Avg Forecast | $13.40M | $10.95M | $8.37M | $6.92M | $24.78M | $23.61M | $18.74M | $15.13M | $19.93M | $20.29M | $20.31M | $72.58M | $22.46M | $20.43M | $54.55M | $16.39M | $18.84M | $26.12M | $17.81M | $28.54M | $25.80M | $9.85M | $8.47M | $10.78M | $13.48M | $6.14M | $3.93M | $9.71M | $326.02K | $290.30K |
| High Forecast | $13.40M | $10.95M | $8.37M | $6.92M | $55.99M | $23.61M | $18.74M | $30.63M | $80.12M | $20.29M | $20.31M | $72.58M | $22.46M | $20.43M | $102.10M | $19.67M | $35.27M | $31.34M | $21.37M | $34.25M | $48.28M | $11.82M | $10.16M | $12.94M | $16.17M | $7.36M | $4.72M | $11.66M | $391.23K | $348.36K |
| Low Forecast | $13.40M | $10.95M | $8.37M | $6.92M | $4.30M | $23.61M | $18.74M | $374.42K | $1.57M | $20.29M | $20.31M | $72.58M | $22.46M | $20.43M | $13.52M | $13.12M | $4.67M | $20.89M | $14.25M | $22.83M | $6.39M | $7.88M | $6.77M | $8.63M | $10.78M | $4.91M | $3.14M | $7.77M | $260.82K | $232.24K |
| Surprise % | - | - | - | - | - | - | - | 1.53% | 1.21% | 1.15% | 1.12% | 0.29% | 1.48% | - | 0.62% | 1.50% | 2.03% | 0.68% | 0.91% | 0.30% | 0.55% | 1.09% | 1.93% | 1.00% | 0.76% | 0.78% | 1.36% | 0.63% | 14.09% | 12.68% |
Arrowhead Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $18.74M, based on 4 Wall Street analysts, with a range of $18.74M to $18.74M. The forecast indicates a -19.18% fall compared to ARWR last annual SG&A of $23.19M (Dec 23).
Arrowhead Pharmaceuticals EPS Forecast
| Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Jun 18 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 7 | 4 | 4 | 9 | 7 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 3 | 4 | 8 | 5 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 | 6 | 14 | 15 | 15 |
| EPS | - | - | - | - | - | - | - | $-1.24 | $-1.03 | $-0.96 | $0.46 | $-0.39 | $-0.81 | - | $0.42 | $-0.60 | $-0.61 | $-0.29 | $-0.26 | $-0.20 | $-0.47 | $-0.13 | $-0.20 | $-0.03 | $0.12 | $0.21 | $0.25 | $0.13 | $-0.18 | $-0.18 |
| Avg Forecast | $-1.14 | $-1.23 | $-1.29 | $-1.27 | $-0.97 | $-0.53 | $-0.47 | $-0.80 | $-0.61 | $-0.57 | $-0.62 | $0.37 | $-0.58 | $-0.57 | $0.14 | $-0.45 | $0.05 | $-0.14 | $0.10 | $0.12 | $0.10 | $-0.12 | $-0.11 | $0.02 | $0.16 | $0.28 | $0.20 | $0.86 | $-0.18 | $-0.18 |
| High Forecast | $-1.14 | $-1.23 | $-1.29 | $-1.27 | $0.83 | $-0.53 | $-0.47 | $-0.30 | $0.76 | $-0.57 | $-0.62 | $0.37 | $-0.58 | $-0.57 | $0.31 | $-0.01 | $0.10 | $-0.00 | $0.22 | $0.26 | $0.21 | $-0.00 | $-0.00 | $0.05 | $0.35 | $0.61 | $0.42 | $1.03 | $-0.14 | $-0.14 |
| Low Forecast | $-1.14 | $-1.23 | $-1.29 | $-1.27 | $-2.30 | $-0.53 | $-0.47 | $-1.15 | $-1.00 | $-0.57 | $-0.62 | $0.37 | $-0.58 | $-0.57 | - | $-0.95 | - | $-0.29 | - | - | - | $-0.25 | $-0.23 | - | - | $0.01 | - | $0.68 | $-0.22 | $-0.22 |
| Surprise % | - | - | - | - | - | - | - | 1.55% | 1.69% | 1.69% | -0.74% | -1.05% | 1.39% | - | 2.90% | 1.34% | -12.68% | 2.11% | -2.52% | -1.65% | -4.75% | 1.13% | 1.85% | -1.40% | 0.73% | 0.74% | 1.26% | 0.15% | 1.00% | 1.00% |
According to 5 Wall Street analysts, Arrowhead Pharmaceuticals's projected average Quarter EPS for Jun 23 is $-0.57, with a low estimate of $-0.57 and a high estimate of $-0.57. This represents a -223.76% decrease compared to ARWR previous annual EPS of $0.46 (Mar 23).
Arrowhead Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| WVE | Wave Life Sciences | $5.86 | $14.00 | 138.91% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $21.49 | $45.38 | 111.17% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| PRQR | ProQR Therapeutics | $1.85 | $3.63 | 96.22% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| BMRN | BioMarin Pharmaceutical | $84.90 | $111.41 | 31.22% | Buy |
| INCY | Incyte | $63.56 | $81.00 | 27.44% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| IONS | Ionis Pharmaceuticals | $42.19 | $50.84 | 20.50% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
ARWR Forecast FAQ
Is Arrowhead Pharmaceuticals a good buy?
Yes, according to 10 Wall Street analysts, Arrowhead Pharmaceuticals (ARWR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 70.00% of ARWR's total ratings.
What is ARWR's price target?
Arrowhead Pharmaceuticals (ARWR) average price target is $45.38 with a range of $27 to $75, implying a 111.17% from its last price of $21.49. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Arrowhead Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for ARWR stock, the company can go up by 111.17% (from the last price of $21.49 to the average price target of $45.38), up by 249.00% based on the highest stock price target, and up by 25.64% based on the lowest stock price target.
Can Arrowhead Pharmaceuticals stock reach $30?
ARWR's average twelve months analyst stock price target of $45.38 supports the claim that Arrowhead Pharmaceuticals can reach $30 in the near future.
What is Arrowhead Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $27 price target for Arrowhead Pharmaceuticals (ARWR) this month, up 25.64% from its last price of $21.49. Compared to the last 3 and 12 months, the average price target increased by 102.42% and increased by 95.44%, respectively.
What are Arrowhead Pharmaceuticals's analysts' financial forecasts?
Arrowhead Pharmaceuticals's analysts financial forecasts for the fiscal year (Sep 2024) are as follows: average revenue is $184.2M (high $288.78M, low $105.31M), average EBITDA is $-115M (high $-65.67M, low $-180M), average net income is $-37.086M (high $299.17M, low $-295M), average SG&A $82.27M (high $128.97M, low $47.03M), and average EPS is $-2.773 (high $-0.466, low $-4.448). ARWR's analysts financial forecasts for the fiscal year (Sep 2025) are as follows: average revenue is $88.74M (high $88.74M, low $88.74M), average EBITDA is $-55.336M (high $-55.336M, low $-55.336M), average net income is $-612M (high $-612M, low $-612M), average SG&A $39.63M (high $39.63M, low $39.63M), and average EPS is $-4.931 (high $-4.931, low $-4.931).
Did the ARWR's actual financial results beat the analysts' financial forecasts?
Based on Arrowhead Pharmaceuticals's last annual report (Sep 2023), the company's revenue was $240.74M, which missed the average analysts forecast of $298.05M by -19.23%. Apple's EBITDA was $-202M, beating the average prediction of $-186M by 8.95%. The company's net income was $-205M, missing the average estimation of $165.65M by -223.92%. Apple's SG&A was $92.55M, missing the average forecast of $133.11M by -30.47%. Lastly, the company's EPS was $-1.92, beating the average prediction of $-1.426 by 34.64%. In terms of the last quarterly report (Dec 2023), Arrowhead Pharmaceuticals's revenue was $3.55M, missing the average analysts' forecast of $33.87M by -89.52%. The company's EBITDA was $-129M, beating the average prediction of $-21.121M by 511.05%. Arrowhead Pharmaceuticals's net income was $-133M, beating the average estimation of $-99.487M by 33.55%. The company's SG&A was $23.19M, beating the average forecast of $15.13M by 53.32%. Lastly, the company's EPS was $-1.24, beating the average prediction of $-0.801 by 54.80%